Floatz logo

Therapeutic Asset Ratings

374 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
erw316
Advanced HR+/HER2- Breast Cancer
Novartis PharmaceuticalsP1/2CC (45)
gvv858
Advanced HR+/HER2- Breast Cancer
Novartis PharmaceuticalsP1/2CC (45)
LEUPROLIDE
Advanced HR+/HER2- Breast Cancer
Novartis PharmaceuticalsP1/2CC (45)
Ribociclib
Advanced HR+/HER2- Breast Cancer
Novartis PharmaceuticalsP1/2CC (45)
tno155
Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis PharmaceuticalsP1/2CC (45)
tno155
Lung Cancer
Novartis PharmaceuticalsP1/2CC (45)
tno155
Colorectal Carcinoma
Novartis PharmaceuticalsP1/2CC (45)
tno155
KRAS G12C Mutant Solid Tumors
Novartis PharmaceuticalsP1/2CC (45)
tno155
Lung Neoplasm
Novartis PharmaceuticalsP1/2CC (45)
Tulmimetostat
T-Cell Non-Hodgkin Lymphoma
Novartis PharmaceuticalsP1/2CC (45)
Tulmimetostat
Malignant Mesothelioma
Novartis PharmaceuticalsP1/2CC (45)
Tulmimetostat
Castration-Resistant Prostate Carcinoma
Novartis PharmaceuticalsP1/2CC (45)
Zoladex
Advanced HR+/HER2- Breast Cancer
Novartis PharmaceuticalsP1/2CC (45)
Magrolimab
Myelodysplastic Syndrome
Novartis PharmaceuticalsP2CC (44)
68ga-ff58
Gastroesophageal Adenocarcinoma
Novartis PharmaceuticalsP1CC (44)
FULVESTRANT
Neuroblastoma
Novartis PharmaceuticalsP1CC (44)
Letrozole
Neuroblastoma
Novartis PharmaceuticalsP1CC (44)
LEUPROLIDE
Neuroblastoma
Novartis PharmaceuticalsP1CC (44)
Opnurasib
Small Cell Lung Carcinoma
Novartis PharmaceuticalsP1CC (44)
Ribociclib
Neuroblastoma
Novartis PharmaceuticalsP1CC (44)
Zoladex
Neuroblastoma
Novartis PharmaceuticalsP1CC (44)
111in-etn029
Gastroenteropancreatic Neuroendocrine Carcinoma
Novartis PharmaceuticalsP1CC (43)
111in-etn029
Pulmonary Large Cell Neuroendocrine Carcinoma
Novartis PharmaceuticalsP1CC (43)
111in-etn029
Prostate Neuroendocrine Neoplasm
Novartis PharmaceuticalsP1CC (43)
177lu-dfc413
Breast Carcinoma
Novartis PharmaceuticalsP1CC (43)
Showing 201 to 225 of 374 assets
PreviousPage 9 of 15Next